The approval was based on interim analysis of IMpower110, a global, randomized, open-label, phase 3 trial which evaluated the efficacy and safety of atezolizumab as compared with platinum-based chemotherapy in patients with metastatic non-squamous or squamous NSCLC with EGFR and ALK-WT tumors who had not previously received chemotherapy and who had PD-L1 expression (on at least 1% of TC or of tumor-infiltrating IC) [22]. The gene discussed is EGFR; the disease is neoplasm.